1
|
Ng OH, Erbilgin Y, Firtina S, Celkan T, Karakas Z, Aydogan G, Turkkan E, Yildirmak Y, Timur C, Zengin E, van Dongen JJM, Staal FJT, Ozbek U, Sayitoglu M. Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. Blood Cancer J 2014; 4:e192. [PMID: 24632884 PMCID: PMC3972698 DOI: 10.1038/bcj.2014.12] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2013] [Revised: 12/16/2013] [Accepted: 12/27/2013] [Indexed: 12/29/2022] Open
Abstract
WNT signaling has been implicated in the regulation of hematopoietic stem cells and plays an important role during T-cell development in thymus. Here we investigated WNT pathway activation in childhood T-cell acute lymphoblastic leukemia (T-ALL) patients. To evaluate the potential role of WNT signaling in T-cell leukomogenesis, we performed expression analysis of key components of WNT pathway. More than 85% of the childhood T-ALL patients showed upregulated β-catenin expression at the protein level compared with normal human thymocytes. The impact of this upregulation was reflected in high expression of known target genes (AXIN2, c-MYC, TCF1 and LEF). Especially AXIN2, the universal target gene of WNT pathway, was upregulated at both mRNA and protein levels in ∼40% of the patients. When β-CATENIN gene was silenced by small interfering RNA, the cancer cells showed higher rates of apoptosis. These results demonstrate that abnormal WNT signaling activation occurs in a significant fraction of human T-ALL cases independent of known T-ALL risk factors. We conclude that deregulated WNT signaling is a novel oncogenic event in childhood T-ALL.
Collapse
Affiliation(s)
- O H Ng
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Y Erbilgin
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - S Firtina
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - T Celkan
- Department of Pediatrics Hematology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Z Karakas
- Department of Pediatric Hematology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
| | - G Aydogan
- Pediatric Hematology Division, Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey
| | - E Turkkan
- Pediatric Hematology Division, Istanbul Okmeydani Education and Research Hospital, Istanbul, Turkey
| | - Y Yildirmak
- Pediatric Hematology Division, Ministry of Health Sisli Etfal Education and Research Hospital, Istanbul, Turkey
| | - C Timur
- Pediatric Hematology Division, Medeniyet University Medical Faculty, Istanbul, Turkey
| | - E Zengin
- Pediatric Hematology Division, Kocaeli University Medical Faculty, Kocaeli, Turkey
| | - J J M van Dongen
- Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - F J T Staal
- 1] Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands [2] Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
| | - U Ozbek
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - M Sayitoglu
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| |
Collapse
|
2
|
Bebek N, Özdemir Ö, Sayitoglu M, Hatırnaz O, Baykan B, Gürses C, Sencer A, Karasu A, Tüzün E, Üzün I, Akat S, Cine N, Sargin Kurt G, Imer M, Ozbek U, Canbolat A, Gökyigit A. Expression analysis and clinical correlation of aquaporin 1 and 4 genes in human hippocampal sclerosis. J Clin Neurosci 2013; 20:1564-70. [PMID: 23928039 DOI: 10.1016/j.jocn.2012.12.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2012] [Revised: 11/28/2012] [Accepted: 12/02/2012] [Indexed: 01/26/2023]
Abstract
Mesial temporal sclerosis (MTS) is the most frequent cause of drug resistant symptomatic partial epilepsy. The mechanism and genetic background of this unique pathology are not well understood. Aquaporins (AQP) are regulators of water homeostasis in the brain and are expressed in the human hippocampus. We explored the role of AQP genes in the pathogenetic mechanisms of MTS through an evaluation of gene expression in surgically removed human brain tissue. We analyzed AQP1 and 4 mRNA levels by quantitative real-time polymerase chain reaction and normalized to ABL and cyclophilin genes, followed by immunohistochemistry for AQP4. Relative expressions were calculated according to the delta Ct method and the results were compared using the Mann-Whitney U test. Brain specimens of 23 patients with epilepsy who had undergone surgery for MTS and seven control autopsy specimens were investigated. Clinical findings were concordant with previous studies and 61% of the patients were seizure-free in the postoperative period. AQP1 and 4 gene expression levels did not differ between MTS patients and control groups. Immunofluorescence analysis of AQP4 supported the expression results, showing no difference. Previous studies have reported contradictory results about the expression levels of AQP in MTS. To our knowledge, only one study has suggested upregulation whereas the other indicated downregulation of perivascular AQP4. Our study did not support these findings and may rule out the involvement of AQP in human MTS.
Collapse
Affiliation(s)
- N Bebek
- Neurology Department, Istanbul Faculty of Medicine, Millet cad., 34390 Capa, Istanbul, Turkey; Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U. Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia. J Int Med Res 2009; 37:1018-28. [DOI: 10.1177/147323000903700406] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
The renin–angiotensin system (RAS) is involved in cell growth, proliferation and differentiation in bone marrow in an autocrine–paracrine manner, and it modulates normal and neoplastic haematopoietic cell proliferation. This study aimed to assess expressions of the RAS components, renin, angiotensinogen and angiotensin-converting enzyme (ACE), during imatinib mesylate treatment of patients with chronic myeloid leukaemia (CML). Expressions of RAS components were studied in patients with CML at the time of diagnosis ( n = 83) and at 3, 6 and 12 months after diagnosis ( n = 35) by quantitative real-time polymerase chain reaction. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. The results of this study confirm that haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib mesylate.
Collapse
Affiliation(s)
- M Sayitoglu
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - IC Haznedaroğlu
- Department of Internal Medicine, Haematology Division, Hacettepe University Medical Faculty, Ankara, Turkey
| | - O Hatirnaz
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Y Erbilgin
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - S Aksu
- Department of Internal Medicine, Haematology Division, Hacettepe University Medical Faculty, Ankara, Turkey
| | - E Koca
- Department of Internal Medicine, Haematology Division, Hacettepe University Medical Faculty, Ankara, Turkey
| | - C Adiguzel
- Department of Internal Medicine, Haematology Division, Marmara University Medical Faculty, Istanbul, Turkey
| | - M Bayik
- Department of Internal Medicine, Haematology Division, Marmara School of Medicine Hospital, Istanbul, Turkey
| | - I Akalin
- Department of Internal Medicine, Haematology Division, Marmara University Medical Faculty, Istanbul, Turkey
| | | | | | - A Unal
- Department of Internal Medicine, Haematology Division, Osmangazi University Medical Faculty, Eskisehir, Turkey
| | - L Kaynar
- Department of Internal Medicine, Haematology Division, Osmangazi University Medical Faculty, Eskisehir, Turkey
| | - E Ovali
- Department of Internal Medicine, Haematology Division, Erciyes University Medical Faculty, Kayseri, Turkey
| | - M Yilmaz
- Department of Internal Medicine, Haematology Division, Erciyes University Medical Faculty, Kayseri, Turkey
| | - M Yenerel
- Department of Internal Medicine, Haematology Division, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - S Dagdas
- Department of Internal Medicine, Haematology Division, Istanbul University Medical Faculty, Istanbul, Turkey
| | - G Ozet
- Department of Internal Medicine, Haematology Division, Istanbul University Medical Faculty, Istanbul, Turkey
| | - C Ar
- Department of Internal Medicine, Haematology Division, Ankara Numune Hospital, Ankara, Turkey
| | - Y Aydin
- Department of Internal Medicine, Haematology Division, Ankara Numune Hospital, Ankara, Turkey
| | - T Soysal
- Department of Internal Medicine, Haematology Division, Ankara Numune Hospital, Ankara, Turkey
| | - B Durgun
- Department of Internal Medicine, Haematology Division, Istanbul University Cerrahpaşa Medical Faculty, Istanbul, Turkey
| | - O Ozcebe
- Department of Internal Medicine, Haematology Division, Hacettepe University Medical Faculty, Ankara, Turkey
| | - A Tukun
- Medical Department, Novartis Oncology Turkey, Istanbul, Turkey
| | - O Ilhan
- Department of Internal Medicine, Genetics Division, Ankara University Medical Faculty, Ankara, Turkey
| | - U Ozbek
- Department of Genetics, Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | | |
Collapse
|